-
Product Insights
Likelihood of Approval Analysis for Hospital Acquired Pneumonia (HAP)
Overview How likely is it that the drugs in Hospital Acquired Pneumonia (HAP) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hospital Acquired Pneumonia (HAP) Overview Hospital-acquired pneumonia (HAP) is defined...
-
Analyst Opinions
Leisure and Hospitality Construction Project Insights and Analytics (Q1 2024)
Leisure and Hospitality Construction Projects Market Overview GlobalData is currently tracking leisure and hospitality building pipeline projects that are cumulatively valued at $1.85 trillion. The projects comprise hotels and resorts along with mixed-use developments that include a significant component of leisure and hospitality-related projects. Furthermore, North America accounts for the highest share of room additions during 2024-2028. The leisure and hospitality construction projects market research report offers a detailed analysis of leisure and hospitality construction projects globally. The report also...
-
Product Insights
NewHospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Hospital Acquired Pneumonia (HAP) Clinical Trial Report Overview A total of 581 HAP clinical trials were conducted as of April 2024. The HAP clinical trial report provides a comprehensive understanding of the HAP clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe...
-
Sector Analysis
General Hospital Supplies Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
General Hospital Supplies Market Report Overview The general hospital supplies market size was $12.7 billion in 2023. Factors such as the solid awareness about ensuring medical facilities will drive the market growth at a CAGR of more than 2% from 2023 to 2033. General hospital supplies support patient care and safety irrespective of the reason they might be visiting the hospital. General hospital supplies form the equipment base of all healthcare facilities in any country. For any kind of treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Avibactam + Aztreonam) in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Avibactam + Aztreonam) in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Avibactam + Aztreonam) in Hospital Acquired Pneumonia (HAP)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SR-1375 in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SR-1375 in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SR-1375 in Hospital Acquired Pneumonia (HAP) Drug Details: SR-1375 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (KSP-1007 + Meropenem) in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (KSP-1007 + Meropenem) in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (KSP-1007 + Meropenem) in Hospital Acquired Pneumonia (HAP)...
-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
MoPW Indonesia – IKN Nusantara Capital Hospital Development – East Kalimantan
The MoPW Indonesia – IKN Nusantara Capital Hospital Development – East Kalimantan project involves the construction of an 11-story hospital in East Kalimantan, Indonesia. Equip yourself with the essential tools needed to make informed and profitable decisions with our MoPW Indonesia – IKN Nusantara Capital Hospital Development – East Kalimantan report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nacubactam in Hospital Acquired Pneumonia (HAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nacubactam in Hospital Acquired Pneumonia (HAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nacubactam in Hospital Acquired Pneumonia (HAP) Drug Details: Nacubactam (RG6080,...